WallStSmart

Intensity Therapeutics, Inc. Common stock (INTS)vsRevolution Medicines Inc (RVMD)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

RVMD leads profitability with a 0.0% profit margin vs 0.0%. INTS earns a higher WallStSmart Score of 26/100 (F).

INTS

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -6.48

RVMD

Avoid

23

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 6.7Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INTS.

RVMDUndervalued (+89.8%)

Margin of Safety

+89.8%

Fair Value

$1883.88

Current Price

$176.35

$1707.53 discount

UndervaluedFair: $1883.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INTS2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

Areas to Watch

INTS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$11.43M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
15.9x4/10

Trading at 15.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INTS

The strongest argument for INTS centers on Price/Book, Debt/Equity.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : INTS

The primary concerns for INTS are Revenue Growth, EPS Growth, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

INTS carries more volatility with a beta of 3.04 — expect wider price swings.

INTS is growing revenue faster at 0.0% — sustainability is the question.

INTS generates stronger free cash flow (-3M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INTS scores higher overall (26/100 vs 23/100). RVMD offers better value entry with a 89.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intensity Therapeutics, Inc. Common stock

HEALTHCARE · BIOTECHNOLOGY · USA

Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. By focusing on enhancing the efficacy of immuno-oncology therapies and reducing systemic side effects, the company addresses critical unmet needs in the oncology market. With a robust research and development pipeline, Intensity Therapeutics aims to advance targeted therapies that empower the immune system to fight cancer more effectively, positioning itself as a leader in improving patient outcomes within a complex and rapidly evolving healthcare landscape.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?